Document is current
Any future updates will be listed below
-
Authors
Enomoto, Noriyuki
Egashira, Ryoko https://orcid.org/0000-0001-7566-546X
Tabata, Kazuhiro
Hashisako, Mikiko
Kitani, Masashi
Waseda, Yuko
Ishizuka, Tamotsu
Watanabe, Satoshi
Kasahara, Kazuo
Izumi, Shinyu
Shiraki, Akira
Miyamoto, Atsushi https://orcid.org/0000-0002-3444-0536
Kishi, Kazuma
Kishaba, Tomoo https://orcid.org/0000-0003-3335-5409
Sugimoto, Chikatosi
Inoue, Yoshikazu https://orcid.org/0000-0003-3994-874X
Kataoka, Kensuke
Kondoh, Yasuhiro
Tsuchiya, Yutaka
Baba, Tomohisa
Sugiura, Hiroaki
Tanaka, Tomonori
Sumikawa, Hiromitsu
Suda, Takafumi
- License Information
-
More Information
Article History
Received: 22 November 2018
Accepted: 1 May 2019
First Online: 14 May 2019
Competing Interests
: N.E., R.E., K.T., M.H., M.K., Y.W., T.I., S.W., K.K., S.I., A.S., A.M., K.K., T.K., C.S., Y.I., K.K., Y.T., T.B., H.S., T.T., H.S. and T.S. declare no competing interests. Dr. Kondoh has received advisory board fees and personal fees from Asahi Kasei Pharma Co., Ltd., Boehringer Ingelheim Co., Ltd., Janssen Pharmaceutical K.K. Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai inc., KYORIN Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Ltd., Novartis Pharma K.K. Co., Ltd., and Shionogi Co., Ltd. outside the submitted work.
